Incyte (INCY) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Incyte (INCY) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.31 Bn | 130.45 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.17 Bn | 77.17 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.25 Bn | 58.07 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 40.01 Bn | 34.92 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.26 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -38.56% |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn | 62.15% |
| 10 | Incyte | 25.53 Bn | 21.00 Bn | 1.57 Bn | 42.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.23% |
| Mar 31, 2026 | 140.88% |
| Dec 31, 2025 | 119.08% |
| Sep 30, 2025 | 55.52% |
| Jun 30, 2025 | 35.88% |
| Mar 31, 2025 | 60.88% |
| Dec 31, 2024 | -29.07% |
| Sep 30, 2024 | -16.33% |
| Jun 30, 2024 | -70.71% |
| Mar 31, 2024 | 46.85% |
| Dec 31, 2023 | 10.30% |
| Sep 30, 2023 | 136.72% |
| Jun 30, 2023 | -11.16% |
| Mar 31, 2023 | 26.62% |
| Dec 31, 2022 | -36.47% |
| Sep 30, 2022 | -4.20% |
| Jun 30, 2022 | 15.30% |
| Mar 31, 2022 | -28.12% |
| Dec 31, 2021 | 101.36% |
| Sep 30, 2021 | 84.00% |